Psilocybin for depression with Ashleigh Murphy-Beiner
My unofficial Vital Study Zine #11 with observations from Vital Psychedelic Training and recent happenings in the space
‘White Light’ from Paul Cocksedge Studio
“We have really explicit conversations about sex, about violence, about death and ego death…”
Plus of course, “Paranoia, wanting to go to the toilet, feeling like you're going to the toilet, and the physical bodily experiences,” says Ashley Murphy-Beiner, psychologist and guide at Imperial College’s landmark ‘PsiloDep 2’ trial, which sounds suitably like a Quatermass movie.
Ashleigh Murphy-Beiner is exactly the sort of impressive individual driving the psychedelic renaissance: a mediation coach and Peruvian ceremony facilitator alongside her studies at Imperial College London, she’s noted for her research on ayahuasca for treating depression too. She’s talking about preparing psychedelic novices for their first trip on synthetic psilocybin, the active ingredient in old-fashioned magic mushrooms. It’s used mostly due to stigma around LSD.
“We let them know we’re not going to judge them on anything weird… although they’re not going to do anything like that, because mainly they're worried it’ll really embarrass them or, or cause shame,” she continues, giving a window into life with depression.
Depression is a ‘global burden’. The main cause of disability and the number one reason for taking time off work affects a quarter of a billion people worldwide, and more in The West. One in six Brits are on anti-depressants, and US figures rose by up to 30% during the COVID-19 crisis. Doomongers will be pleased to know there are plenty more sad stats in this week’s ‘zine.
Imperial College psychologist, meditation coach and ayahuasca advocate Asheligh Murphy-Beiner
Can psychedelics cure long term depression where talk therapy and medications failed? Although arguably still spectacular in comparison to existing treatment, results are frankly not as good as those for psychedelic studies on treating trauma, addiction, and end-of-life crisis. That’s partly because depression mostly remains a mystery, with the widely-accepted ‘serotonin imbalance’ theory recently publicly debunked. Ashleigh calls the causes “biopsychosocial” meaning there are biological, psychological and social implications. Many patients have come crashing down to Earth when faced with the cruel reality of life in late capitalism. Preparation and integration are absolutely essential, say trial patient advocates Ian Roullier and Leone Schneider of advocacy group PsyPAN. Dr Rosalind Watts created a treatment model, Acceptance, Connection and Embodiment to cover the ground between secular dystopian life and the psychedelic experience.
Results of psilocybin for depression trials so far though are certainly optimistic compared to market anti-depressants. A major advantage is that psychedelic treatment opens up the mind, rather than numbing out all feelings, like current anti-depressants are said to. Opportunity and relish can once more be a part of depressive’s mindset. Plus they can dump their daily regime of equally barely-understood serotonin pills with side-effects like a plummeting libido.
This is one subject for which there is certainly no silver bullet. Here’s Ashleigh talking about ayahuasca, and the ACE therapy model used at the trials with Dr Ros, plus the ethics of the trials and therapy itself, and rounding up the trial results on the Chasing Consciousness podcast, all of which you can see on the New Psychonaut YouTube channel.
This week’s topics arranged along Vital’s core learning pillars are below.
Psilocybin patients “experience everything” in contrast to the emotional anaesthsia of SSRI medication.